BioStock: Development in focus for Emplicure after results in PK study

07 March 2023 - 08:22

Emplicure has focused on development work during the fourth quarter of 2022. During the period, the company completed an exploratory PK study with Empli03, which showed a steady profile and extended release. After the results were presented, the company announced that the development of the candidate is progressing. Emplicure also initiated a collaboration with OnDosis in the field of pain management. BioStock contacted CEO Håkan Engqvist to find out more about the last quarter.

Read the full article about Emplicure at

Detta är ett pressmeddelande från BioStock – Connecting Innovation & Capital.

Provided by: Cision
Nasdaq First North GM Stockholm (Sweden)
Emplicure AB
Emplicure is a pharmaceutical company that develops new innovative drugs based on the combination of already approved active substances and advanced materials science in bioceramics. The product portfolio initially focuses on drugs for chronic pain and with addictive properties....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More